Fig. 3
From: The timeline of epigenetic drug discovery: from reality to dreams
Second-generation DNMT inhibitors. The nucleoside analogue DNMT inhibitors zebularine (compound 13), CP-4200 (compound 14), and guadecitabine (compound 15) have reached clinical development
